Navigation Links
Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
Date:4/24/2008

e brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharmasset.com

Office: (609) 613-4125

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that we cannot enroll enough patients for the Phase 3 registration clinical trial for clevudine, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
2. Pharmasset Receives $10 Million of Working Capital
3. Pharmasset Appoints Herbert J. Conrad as a Director
4. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
5. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
6. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
7. Pharmasset Reports Fiscal Year End 2007 Financial Results
8. Pharmasset Appoints Michael Rogers as Chief Development Officer
9. Pharmasset to Present at Three Investor Conferences in November 2007
10. Pharmasset Accesses up to $30 Million of Working Capital
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... are based on electrons, but one of the most ... i.e. circuits based on light (photons) instead of electrons. ... a stream of single photons and control their direction. ... attempts to achieve this control, but now scientists at ... steady stream of photons emitted one at a time ...
(Date:8/29/2014)... Pittsburgh, PA (PRWEB) August 29, 2014 ... Chairman, Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, ... JASIS on September 5, 2014. JASIS , Asia’s ... September 3-5, 2014, in Makuhari Messe, Japan. , ... New Tools for Bioanalysis from Single Molecules to Single ...
(Date:8/29/2014)... California (PRWEB) August 29, 2014 ... of Energy's 2014 Hydrogen Production R&D Award ... -- by splitting water using sunlight. , Shared ... (NREL) and the University of Nevada, Las Vegas ... work developing models of photoelectrochemical solar-hydrogen production and ...
(Date:8/29/2014)... August 29, 2014 Intrinsic Imaging, ... certified, GAMP® 5 compliant imaging core lab, announced ... Phase II clinical trial to assess a new ... this trial, Intrinsic Imaging will provide comprehensive imaging ... protocol and charter development, site qualification, site training ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Livermore Team Awarded for Hydrogen Production Research 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... Consistent,Electronic Health Record for All Citizens Using City ... GREAT RIVER, N.Y., Oct. 16 Netsmart Technologies, ... for health and,human services organizations, today announced it ... contract by the City and County of San,Francisco, ...
... access to advanced gene-sequencing,technologies and gives new hope ... 16 Swedish Neuroscience,Institute (SNI) today announced that ... Hill Campus, the Center for Advanced Brain Tumor,Treatment ... patients diagnosed,with both benign and malignant brain tumors. ...
... Phase 3 CAPACITY Program - ... rate in CAPACITY -, BRISBANE, Calif., Oct. 16 ... 16, 2008, the Japanese,Ministry of Health, Labor and Welfare (MHLW) ... Ltd. to market pirfenidone,for the treatment of patients with idiopathic ...
Cached Biology Technology:Netsmart Technologies Selected by City and County of San Francisco to Provide Integrated Behavioral Healthcare Software System 2Netsmart Technologies Selected by City and County of San Francisco to Provide Integrated Behavioral Healthcare Software System 3Swedish in Seattle Unveils State-of-the-Art Brain Tumor Center Combining Advanced Treatment With Innovation in Research 2Swedish in Seattle Unveils State-of-the-Art Brain Tumor Center Combining Advanced Treatment With Innovation in Research 3Swedish in Seattle Unveils State-of-the-Art Brain Tumor Center Combining Advanced Treatment With Innovation in Research 4InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF 2InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF 3InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF 4
(Date:9/1/2014)... Mass-- Conventional wisdom has long held that corals ... coral reefs are passive organisms that rely ... such as nutrients and oxygen. But now scientists ... (WIS) in Israel have found that they are ... water into turbulent patterns that greatly enhance their ...
(Date:9/1/2014)... About 50 years ago, electron microscopy revealed the presence ... around and disappear. But scientists still don,t know what ... of proteins are believed to be crucial to the ... new approach to disease treatment., In the Journal ... call to investigators from various backgrounds, from biophysics to ...
(Date:8/31/2014)... A new blood test provides a fast and ... new proof-of-concept study shows. The newly developed test ... to detect active tuberculosis in children. The test ... tests in combination with speed of a blood ... for the diagnosis of tuberculosis in children, particularly ...
Breaking Biology News(10 mins):Nature's tiny engineers 2Nature's tiny engineers 3Scientists call for investigation of mysterious cloud-like collections in cells 2New tuberculosis blood test in children is reliable and highly specific 2
... German . , EASY-HIT** is a new cell-based ... This system was developed under the leadership of Professor Ruth ... the system are cultured human cells that allow HIV to ... producing a red fluorescent protein. The EASY-HIT technology can be ...
... Colo. (December 1, 2010) A major new study ... fetus to those smells and flavors, but physically changes the ... the future. "This highlights the importance of eating ... and nursing," said Josephine Todrank, PhD, who conducted the two-year ...
... from the UC Davis Health System have found that ... are significantly reduced in patients in the Sacramento area ... that affects about one in three U.S. adults and ... The study is the first to examine vitamin-D ...
Cached Biology News:A powerful new technology to identify HIV inhibitors 2Study shows pregnant mother's diet impacts infant's sense of smell 2Study finds low vitamin-d levels in northern California residents with metabolic syndrome 2Study finds low vitamin-d levels in northern California residents with metabolic syndrome 3Study finds low vitamin-d levels in northern California residents with metabolic syndrome 4
... cells for DNA isolation. Designed ... (includes 96 well plate adapters from ... the entire plate length (max capacity ... be used for soil, microorganisms, animal ...
Phospho- (Ser) 14-3-3 Binding Motif (4E2) Mouse mAb...
Rat polyclonal to acetyl Salicylic Acid ( Abpromise for all tested applications)....
Drugs and NO-drug Rat Anti-conjugated Acetyl Salicylic Acid Polyclonal Antibody...
Biology Products: